![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma (American Society of Hematology) View |
![]() |
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma (Touch Medical Media) View |
![]() |
Multiple Myeloma Update | Shaji Kumar, MD | 2022 West Oncology | Updates for APPs u0026 Nurses (Total Health | Oncology) View |
![]() |
What’s on the Horizon for Myeloma (OncLive) View |
![]() |
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis (ecancer) View |
![]() |
Dr. Shaji Kumar - Mayo Clinic - Rochester, USA (Oncology Information Group) View |
![]() |
Upfront Therapy for Myeloma; Impact on Choice at Relapse (OncLive) View |
![]() |
Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMM (International Myeloma Foundation) View |
![]() |
Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Case Study 1: The Value of KRd in Multiple Myeloma (OncLive) View |